marked.bio

Company

BridgeBio Oncology Therapeutics

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

BBO-10203 3pembrolizumab 2cetuximab 1BBO-8520 1trastuzumab 1fulvestrant 1ribociclib 1bevacizumab 1

Trials

3 of 3 trials shown

  1. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2025Primary completion 2027-08 NCT06917079

    BBO-11818pembrolizumabcisplatincarboplatinpemetrexedcetuximabmFOLFOX6BBO-10203mFOLFIRINOXgemcitabinenab-paclitaxel

    …ced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation

    KRAS G12CKRAS G12DNon-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)

  2. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2031-04 NCT06343402

    BBO-8520pembrolizumabBBO-10203

    …umented locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS G12C mutation

    KRAS G12CNon-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C

  3. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    Recruiting Phase 1 BridgeBio Oncology Therapeutics Started 2024Primary completion 2028-11 NCT06625775

    BBO-10203trastuzumabfulvestrantribociclibFOLFOXbevacizumab

    …-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aN…

    KRAS G12CKRAS G12DPIK3CA activating mutationSolid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors